Evidence map›Paper›PMID 31549012›Full record

ArticleAnnals of gastroenterological surgery2019

Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01).

Yasutoshi Kimura, Toru Nakamura, Tsuyoshi Hayashi, Masaki Kuwatani, Masayo Motoya, Makoto Yoshida, Masafumi Imamura, Minoru Nagayama, Hiroshi Yamaguchi, Keisuke Yamakita and 6 more

Open access · goldAbstract read
In one paragraph

Article in Annals of gastroenterological surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Yasutoshi KimuraDepartment of Surgery Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.ORCID https://orcid.org/0000-0002-7790-9250
Toru NakamuraHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Tsuyoshi HayashiHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Masaki KuwataniHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Masayo MotoyaHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Makoto YoshidaHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Masafumi ImamuraDepartment of Surgery Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.
Minoru NagayamaDepartment of Surgery Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.
Hiroshi YamaguchiDepartment of Surgery Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.
Keisuke YamakitaHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Takuma GotoHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Yusuke SakuharaHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Kuniyuki TakahashiHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Hiroyuki MaguchiHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Satoshi HiranoHokkaido Pancreatic Cancer Study Group; HOPS Sapporo Japan.
Ichiro TakemasaDepartment of Surgery Surgical Oncology and Science Sapporo Medical University School of Medicine Sapporo Japan.
Sapporo Medical University · JPHokkaido University · JPSapporo Science Center · JPAsahikawa Medical University · JPTonan Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimEffective multidisciplinary approaches for unresectable pancreatic cancer (UR-PC) that include modern chemotherapeutic regimens and subsequent conversion surgery (CS) are being developed. The aim of this study was to evaluate outcomes of patients clinically diagnosed with UR-PC, focusing on the efficacy of CS.

methodsPatients ineligible for two multicenter phase II studies conducted by the Hokkaido Pancreatic Cancer Study Group (HOPS) were recruited. Sequential treatment regimens, conversion to radical surgery, and overall survival (OS) were analyzed by multidetector computed tomography (MDCT)-based UR factors. Univariate and multivariate analyses were performed to identify predictors of OS.

resultsSixty-six of 247 intended recruits for HOPS studies from October 2013 to April 2016 were included. Unresectability was due to locally advanced (LA) disease and metastasis (M) in 42 and 24 patients, respectively. Induction therapy began with chemotherapy (CT) and chemoradiotherapy (CRT) in 44 and 17 patients, respectively, of whom 23 received modern CT regimens. Radical surgery was completed in 12 (LA, 10; M, two) with a median treatment interval of 10.3 months (range, 2-32). Eleven patients (91.6%) achieved pathological R0 resection. Median OS was significantly longer in patients who underwent CS than those who did not (44.1 vs 14.5 months,

conclusionConversion surgery after a favorable response to sequential treatment might prolong survival in patients with UR-PC. Precise diagnosis on MDCT followed by sequential multimodal anticancer treatment is essential.

Indexed as

locally advancedmetastaticmultidisciplinary treatmentradical surgeryunresectable pancreatic cancer

Identifiers

PMID31549012
PMCPMC6749954
OpenAlexW2959830673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.